Early Phase 1 N=10 Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=94 Natural History of Chronic Urticaria
Chronic Urticaria
Primary: Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. — 18.5; 54; 67.7 percentage of participants
Phase 3 N=418 Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Change From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment — -10.11; -9.66; -5.87 Score on a scale — p=<0.001
Phase 4 N=136 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
CHRONIC SPONTANEOUS URTICARIA
Primary: Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12 — 75.0 percent of participants
Phase 2 N=134 A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 — -19.16; -24.05; -11.25; -15.69 Score on a Scale — p=0.0559
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 3 N=319 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Chronic Idiopathic Urticaria
Primary: Change From Baseline to Week 12 in the Weekly Itch Severity Score — -3.63; -6.46; -6.66; -9.40 Units on a scale — p=0.0010
Phase 3 N=218 Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients
Chronic Spontaneous Uriticaria
Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -10.22; -8.80; -6.51 Units on a scale — p=<0.001
Phase 2 N=31 Cold Urticaria Treatment With Xolair
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
Phase 2 N=183 Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 — -13.6; -18.4; -13.5; -14.7 score on a scale — p=0.99
Phase 4 N=18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
Urticaria Chronic
Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days
Phase 3 N=323 A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Chronic Idiopathic Urticaria
Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -5.14; -5.87; -8.14; -9.77 Units on a scale — p=0.4637
Phase 2 N=90 A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Chronic Idiopathic Urticaria
Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601
Phase 3 N=619 To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Primary: Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg Groups — -9.25; -9.96 score on a scale
Phase 2 N=136 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
Urticaria · Chronic Spontaneous Urticaria · Chronic Idiopathic Urticaria
Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12 — -17.90; -17.25; -19.83; -23.91 scores on a scale — p=0.8298
Phase 2 N=49 Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Chronic Urticaria
Primary: Change in the Weekly Urticaria Activity Score (UAS7) From Baseline to the End of the Study (Week 24) — -17.8; -5.8 Units on a scale
Phase 3 N=336 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Chronic Idiopathic Urticaria
Primary: Percentage of Participants With Adverse Events — 78.3; 83.7 Percentage of participants
Phase 3 N=91 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Chronic Spontaneous Urticaria · Angioedema
Primary: Mean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)…
Phase 2 N=49 Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous Urticaria
Primary: Change From Baseline of Weekly Urticaria Activity Score (UAS7) at Week 24 — -20.36; -22.50; -21.26 Score on a scale
Phase 2 N=382 Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
Chronic Spontaneous Urticaria
Primary: Percentage of Participants With Complete Hives Response (HSS7=0) — 30.2; 51.2; 42.4; 25.9 Percentage of participants — p=<.05
Phase 2 N=28 Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
Chronic Idiopathic Urticaria
Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores
Phase 4 N=886 CUTE (Chronic Urticaria Treatment Evaluation)
Chronic Idiopathic Urticaria
Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001
Phase 4 N=10 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Chronic Urticaria
Primary: Change in the Basophil Proteome — 4; 0; 3 Participants
Phase 4 N=205 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
Urticaria
Primary: Percentage of Participants Who Experienced Clinical Worsening in CIU as Assessed by Urticaria Activity Score Over 7 Days (UAS7) (Clinical Worsening: UAS7 Greater Than or…
Phase 3 N=455 A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
Chronic Spontaneous Urticaria
Primary: Mean Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 (Scenario 1 With UAS7 as Primary Efficacy Endpoint) — -19.41; -11.73 Unit on a scale — p=<…
Phase 3 N=397 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Weekly Itch Severity Score at Week 24 — -6.01; -10.24; -4.81; -7.68 score on a scale — p=0.0005
Phase 2 N=10 Omalizumab in Severe and Refractory Solar Urticaria
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
Phase 3 N=608 Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Chronic Urticaria
Primary: Change From Baseline in the ISS7 at Week 12, TEV-45779 High Dose Compared to XOLAIR High Dose (For European Medicines Agency [EMA] Submission) — -10.92; -10.61 units on…
Phase 2 N=226 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Chronic Spontaneous Urticaria
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (AE) — 190 Participants
Phase 4 N=314 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
Chronic Idiopathic Urticaria
Primary: Change in the Urticaria Activity Score (UAS) From Baseline to the Final Week for Desloratadine 5 mg Versus Desloratadine 20 mg — -1.0; -1.0; -1.1; 2.9 Units on a scale…